Monday, November 1, 2010

FDA approves new indication for Afinitor (everolimus)

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder.
This approval was for treatments of SEGA that can not be treated with surgery.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231793.htm

No comments:

Post a Comment